Abstract
Montelukast sodium (Singulair®, Merck and Co., Inc., Whitehouse Station, NJ) is a selective and orally-active leukotriene receptor antagonist with demonstrated effectiveness for treating allergic asthma and allergic rhinitis in adults and children as young as 12 months of age for allergic asthma and 6 months of age for allergic rhinitis. It was recently approved in the US for prevention of exercise-induced bronchoconstriction in patients who are ≥ 15 years of age. This paper updates a prior review of the data on the clinical efficacy of montelukast published in this journal.
Acknowledgements
The author would like to acknowledge the editorial assistance and technical expertise of Judith Farrar, PhD, FAAAAI in the preparation of this manuscript.
Disclosure
W Storms has carried out research studies at Alcon, Atlanta, AstraZeneca, BMS, Genentech, GSK, Medpointe, Merck, Novartis, sanofi-aventis and Schering.
He is also a Consultant/Board member for Adams, Alcon, Atlanta, AstraZeneca, Consumer Reports/Consumers Union, Efficas, Exaeris, Genentech, Greer, GSK, Hoffmann-La Roche, Inspire, Isis, Ivax, King, Medpointe, Merck, Nexcura, Novartis, sanofi-aventis, Schering, Sepracor, Strategic Biosciences, Strategic Pharmaceutical Advisors, TREAT Foundation and Wyeth, and serves on the Speaker's Bureau for Abbott, Alcon, AstraZeneca, Genentech, Medpointe, Merck, Novartis, Pfizer, sanofi-aventis and Schering.